WordNet

the writing point of a pen (同)pen nib

PrepTutorEJDIC

ペン先 / (一般的に)とがった部分,先端(tip) / (鳥の)くちばし

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/08/11 17:44:57」(JST)

wiki en

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by the U.S. Food and Drug Administration.^[1]^[2]^[3] Pazopanib may also be active in ovarian cancer^[4] Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.^[4]

References[edit source | edit]

^ "FDA Approves GlaxoSmithKline's Votrient(TM) For Advanced Renal Cell Cancer". Medical News Today. 20 October 2009. Retrieved 8 June 2010.
^ Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schoffski, P.; Collin, F.; Pandite, L. et al. (2009). "Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients with Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)". Journal of Clinical Oncology 27 (19): 3126. doi:10.1200/JCO.2008.21.3223. PMID 19451427. |displayauthors= suggested (help) edit
^ "FDA Approves Glaxo Cancer Drug Votrient". Reuters. 26 April 2012. Retrieved 27 April 2012.
^ ^a ^b "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 転移性の胃腸膵管系神経内分泌腫瘍：腫瘍増殖およびホルモン過剰分泌による症状を管理
するための全身治療の選択肢 metastatic gastroenteropancreatic neuroendocrine tumors systemic therapy options to control tumor growth and symptoms of hormone hypersecretion
2. 分子標的薬である血管新生阻害剤の毒性：心血管系以外への影響 toxicity of molecularly targeted antiangiogenic agents non cardiovascular effects
3. 分子標的薬である血管新生阻害剤の毒性：心血管系への影響 toxicity of molecularly targeted antiangiogenic agents cardiovascular effects
4. 進行腎細胞癌に対する抗血管新生療法および分子標的療法 anti angiogenic and molecularly targeted therapy for advanced renal cell carcinoma
5. 上皮性卵巣癌、卵管癌、または腹膜癌における血管新生阻害剤の作用 the role of angiogenesis inhibitors in epithelial carcinoma of the ovary fallopian tube or peritoneum

English Journal

Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis.

Ensslin CJ, Rosen AC, Wu S, Lacouture ME.SourceDermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Journal of the American Academy of Dermatology.J Am Acad Dermatol.2013 Nov;69(5):708-20. doi: 10.1016/j.jaad.2013.06.038. Epub 2013 Aug 24.
BACKGROUND: Pruritus has been anecdotally described in association with targeted cancer therapies. The risk of pruritus has not been systematically ascertained.OBJECTIVE: A systematic review and meta-analysis of the literature was conducted for axitinib, cetuximab, dasatinib, erlotinib, everolimus,
PMID 23981682

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.

Dranitsaris G, Schmitz S, Broom RJ.SourceUniversity of Ioannina, Ioannina, Greece, george.dranitsaris@gmail.com.
Journal of cancer research and clinical oncology.J Cancer Res Clin Oncol.2013 Nov;139(11):1917-26. doi: 10.1007/s00432-013-1510-5. Epub 2013 Sep 14.
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) and a good performance status typically receive an anti-vascular endothelial growth factor receptor (VEGFR) TKI (sunitinib or pazopanib) as initial therapy. Upon disease progression or intolerance, there are four orally administered ag
PMID 24037486

A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ, Hartigh Jd.SourceDepartment of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands; Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Electronic address: P.vanErp@akf.umcn.nl.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.J Chromatogr B Analyt Technol Biomed Life Sci.2013 Oct 15;937:33-43. doi: 10.1016/j.jchromb.2013.08.013. Epub 2013 Aug 17.
A sensitive, sophisticated and practical bioanalytical assay for the simultaneous determination of six tyrosine kinase inhibitors (imatinib, sunitinib, nilotinib, dasatinib, pazopanib, regorafenib) and two active metabolites (N-desmethyl imatinib and N-desethyl sunitinib) was developed and validated
PMID 24013127

Japanese Journal

経験と考察進行性軟部肉腫に対するパゾパニブ塩酸塩の治療効果と有害事象

鈴木賀代,安田剛敏,渡邉健太 [他]
整形外科 = Orthopedic surgery 66(5), 418-422, 2015-05
NAID 40020456323

後腹膜脂肪肉腫再発3例に対するパゾパニブの使用経験

小泉淳,井上高光,高山孝一朗 [他],高橋誠,沼倉一幸,鶴田大,秋濱晋,齋藤満,成田伸太郎,土谷順彦,佐藤滋,羽渕友則
泌尿器科紀要 = Acta urologica Japonica 61(4), 153-158, 2015-04
… Pazopanib, a novel tyrosine kinase inhibitor, is an effective therapeutic agent for patients with advanced soft tissue sarcoma. … Here we report three patients with recurrent retroperitoneal liposarcoma who were treated with pazopanib. … Because of the lack of response to chemotherapy, 400 mg/day of pazopanib was subsequently administered for two weeks. … Pazopanib (600 mg/day) was partially effective for 2 months. …
NAID 120005611425

Primary Pleural Synovial Sarcoma Treated with Pazopanib

Sugitani Arata,Asai Kazuhisa,Kojima Kazuya,Eguchi Yosuke,Kawaguchi Tomoya,Ohsawa Masahiko,Hirata Kazuto
Internal Medicine 54(16), 2051-2055, 2015
… Although treated with pazopanib as second-line chemotherapy, the patient died eight months after the initial presentation. …
NAID 130005092891

Related Pictures

Pazopanib Pazopanib Tablets - Votrient Pazopanib Figure 2 - Related to the endothelial cell Pazopanib approved for soft tissue sarcoma ODAC Recommends Pazopanib But Not Pazopanib (GW-786034)|VEGFR/PDGFR/FGFR Figure 1 : Pazopanib : Nature Reviews Drug Votrient (pazopanib) is indicated for the

★リンクテーブル★

リンク元	「nib」「モテサニブ」「パゾパニブ」

「nib」

Pazopanib
Systematic (IUPAC) name
	5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide
Clinical data
Trade names	Votrient
AHFS/Drugs.com	monograph
MedlinePlus	a610013
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	D (US)
Legal status	℞-only (US)
Routes	Oral
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hepatic (CYP3A4, 1A2 and 2C8-mediated)
Half-life	31 hours (mean)
Excretion	Mostly fecal
Identifiers
CAS number	444731-52-6
ATC code	L01XE11
PubChem	CID 11525740
ChemSpider	9700526
UNII	7RN5DR86CK
ChEMBL	CHEMBL477772
Chemical data
Formula	C21H23N7O2S
Mol. mass	437.517 g/mol
	SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C;
	InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H ; Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N ;
(what is this?) (verify);

　　[★]

受容体のリガンド結合部を標的とした小分子化合物。

nib

アキシチニブ axitinib
ボスチニブ bosutinib
ブリバニブ brivanib
カネルチニブ canertinib
セジラニブ cediranib
ダサチニブ dasatinib　チロシンキナーゼ阻害薬　イマチニブ抵抗性の慢性骨髄性白血病、再発又は難治性のフィラデルフィア染色体陽性急性リンパ性白血病
エルロチニブ erlotinib
ゲフィチニブ gefitinib
イマチニブ imatinib　チロシンキナーゼ阻害薬　CML、CKIT(CD117)陽性消化管間質腫瘍、
ラパチニブ lapatinib
レスタウルチニブ lestaurtinib
リニファニブ linifanib
ロナファーニブ lonafarnib
ネラチニブ neratinib
ニブリン nibrin
ニロチニブ nilotinib　チロシンキナーゼ阻害薬　イマチニブ抵抗性の慢性期又は移行期の慢性骨髄性白血病
パゾパニブ pazopanib
ペガプタニブ pegaptanib
ラニビズマブ ranibizumab
セマキシニブ semaxinib
ソラフェニブ sorafenib
スニチニブ sunitinib　VEGFRやPDGFRチロシンキナーゼ阻害薬　イマチニブ抵抗性の消化管間質腫瘍、根治切除不能又は転移性の腎細胞癌
ティピファニブ tipifarnib
バンデタニブ vandetanib
バタラニブ vatalanib

「モテサニブ」

　　[★]

英: motesanib
開発名: AMG706

多キナーゼ阻害薬の一つ

多キナーゼ阻害薬には
スニチニブ sunitinib
ソラフェニブ sorafenib
ヴァラチニブ valatinib

オーロラ阻害薬　パゾパニブ pazopanibというのもあるらしい

作用機序
血管内皮増殖因子受容体 VEGFR1,2,3、血小板由来増殖因子受容体 PDGFR、SCF受容体 c-KITに結合することによる

文献

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.

Cancer Chemother Pharmacol. 2010 Sep 14. [Epub ahead of print]

Benjamin RS, Schoffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L.

PMID 20838998

参考

mikanbox

http://www.mikanbox.com/md-lab/column/imashuku/Column6/column6_25.html

「パゾパニブ」

　　[★]

英: pazopanib
商: ヴォトリエント
化: パゾパニブ塩酸塩 pazopanib hydrochloride

[1] "FDA Approves GlaxoSmithKline's Votrient(TM) For Advanced Renal Cell Cancer". Medical News Today. 20 October 2009. Retrieved 8 June 2010.

[2] Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schoffski, P.; Collin, F.; Pandite, L. et al. (2009). "Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients with Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)". Journal of Clinical Oncology 27 (19): 3126. doi:10.1200/JCO.2008.21.3223. PMID 19451427. |displayauthors= suggested (help) edit

[3] "FDA Approves Glaxo Cancer Drug Votrient". Reuters. 26 April 2012. Retrieved 27 April 2012.

[FierceBiotech-4] "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10.

匿名

検索

案内

案内

pazopanib